Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. EJE PRIZE 2018: A gut feeling about glucagon

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral D/L-3-Hydroxybutyrate stimulates cholecystokinin and insulin secretion and slows gastric emptying in healthy males

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Solrun Vidarsdottir
  • Ferdinand Roelfsema
  • Trea Streefland
  • Jens Juul Holst
  • Jens F Rehfeld
  • Hanno Pijl
Vis graf over relationer
Treatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).
OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind162
Udgave nummer1
Sider (fra-til)75-83
Antal sider9
ISSN0804-4643
DOI
StatusUdgivet - 1 jan. 2010

ID: 31047005